No Subject Date 50 Wellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab) 2023-02-08 49 Wellmarker Bio wins Good Company 'Bio' Award for the 4th Consecutive Year 2022-09-15 48 WMBIO and Oncozen enters into licensing and collaboration agreement on “CMPD” TPD 2022-07-18 47 Wellmarker Bio signs MoU with Isogenica for the development of multiple therapeutic assets 2022-05-31 46 Wellmarker Bio acquires “Certification of Excellence in Employee Invention Promotion” and “Certificate of IP Management Enterprise” 2022-05-18 45 Wellmarker Bio’s Immunotherapy ‘WM-A1’ gets nominated for the government-led R&D support program 2022-05-12 44 Wellmarker Bio and Paik Hospital Ink MoU to develop personalized anticancer drug 2022-04-22 43 Wellmarker Bio Receives Ministry of Food and Drug Safety (MFDS) Approval to Initiate Phase 1 Study of ‘WM-S1-030’ 2022-04-13 42 Wellmarker Bio launches ambitious strategy to achieve Top 50 global pharmaceutical status within 10 years 2022-02-08 41 Wellmarker Bio Announces its latest pipeline news at the Korea Bio Investment Conference 2021 2021-12-09 1 2 3 4 5
